Found 1 result
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
If one assumption has quietly cost pharmaceutical R&D more than any other in the past two decades, it is the conflation of biomarker with drug target. They look similar on a slide. They diverge sharply in clinical trials.